Interleukin-17B (IL-17B)

Interleukin-17B (IL-17B) is a pro-inflammatory cytokine belonging to the IL-17 family and functions primarily through binding to its cell surface receptor IL-17RB[2]. IL-17B is secreted as a non-covalent dimer glycoprotein, highly homologous to its murine ortholog, and is expressed predominantly in the pancreas, small intestine, stomach, and testis, as well as certain immune cells and neurons[2]. Its biological effects include promoting TNF-α and IL-1β production, potentiating inflammatory chemokine expression, and facilitating immune cell trafficking. IL-17B plays a prominent role in diseases characterized by inflammation and has been implicated in tumorigenesis, especially through enhancing cancer cell proliferation, survival, migration, and resistance to chemotherapy agents[2]. Elevated IL-17B and IL-17RB expression is associated with poor patient outcomes in several cancers. Research into neutralizing antibodies and inhibitors of the IL-17B/IL-17RB axis is ongoing for therapeutic intervention.

Other names

IL-17BIL17BIL20NIRFZCYTO7UNQ516/PRO1031MGC138900MGC138901Cytokine Zcyto7Interleukin-20Neuronal interleukin-17-related factorcytokine-like protein ZCYTO7interleukin 20interleukin-17 betaneuronal interleukin-17 related factor

Ligand binding to IL-17RB receptor triggers NF-κB, ERK, JNK, and p38 MAPK signaling[2] Promotes cancer cell survival via activation of anti-apoptotic proteins (e.g., Bcl-2 family)[2] Induces chemokine/cytokine expression for immune cell recruitment[2]